Evidence map›Paper›PMID 28849022›Full record

ArticleMolecular medicine reports2017

Significance of the TMPRSS2:ERG gene fusion in prostate cancer.

Zhu Wang, Yuliang Wang, Jianwen Zhang, Qiyi Hu, Fan Zhi, Shengping Zhang, Dengqi Mao, Ying Zhang, Hui Liang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 115 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Oncogenic gene fusions in cancer: from biology to therapy.Signal transduction and targeted therapy · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. CAP superfamily proteins in human: a new target for cancer therapy.Medical oncology (Northwood, London, England) · 2024
    Review
  16. TNIK in disease: from molecular insights to therapeutic prospects.Apoptosis : an international journal on programmed cell death · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhu WangDepartment of Urology, People's Hospital of Longhua New District of Shenzhen and Affiliated Shenzhen Longhua Hospital of Southern Medical University, Shenzhen, Guangdong 518109, P.R. China.
Yuliang WangDepartment of Urology, Peking University People's Hospital, Beijing 100044, P.R. China.
Jianwen ZhangDepartment of Urology, People's Hospital of Longhua New District of Shenzhen and Affiliated Shenzhen Longhua Hospital of Southern Medical University, Shenzhen, Guangdong 518109, P.R. China.
Qiyi HuDepartment of Urology, People's Hospital of Longhua New District of Shenzhen and Affiliated Shenzhen Longhua Hospital of Southern Medical University, Shenzhen, Guangdong 518109, P.R. China.
Fan ZhiDepartment of Urology, People's Hospital of Longhua New District of Shenzhen and Affiliated Shenzhen Longhua Hospital of Southern Medical University, Shenzhen, Guangdong 518109, P.R. China.
Shengping ZhangDepartment of Urology, People's Hospital of Longhua New District of Shenzhen and Affiliated Shenzhen Longhua Hospital of Southern Medical University, Shenzhen, Guangdong 518109, P.R. China.
Dengqi MaoDepartment of Urology, People's Hospital of Longhua New District of Shenzhen and Affiliated Shenzhen Longhua Hospital of Southern Medical University, Shenzhen, Guangdong 518109, P.R. China.
Ying ZhangDepartment of Urology, People's Hospital of Longhua New District of Shenzhen and Affiliated Shenzhen Longhua Hospital of Southern Medical University, Shenzhen, Guangdong 518109, P.R. China.
Hui LiangDepartment of Urology, People's Hospital of Longhua New District of Shenzhen and Affiliated Shenzhen Longhua Hospital of Southern Medical University, Shenzhen, Guangdong 518109, P.R. China.
Southern Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transmembrane protease serine 2:v‑ets erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) gene fusion is common in prostate cancer, while its functional role is not fully understood. The present study aimed to investigate the significance of the TMPRSS2:ERG gene fusion in human prostate cancers using bioinformatics tools. Comprehensive alteration analysis of TMPRSS2 and ERG in 148 different human cancer studies was performed by cBioPortal, and the mRNA expression level of the ERG gene was evaluated using Oncomine analysis. Furthermore, lentiviral short hairpin (sh)RNA‑mediated knockdown of TMPRSS2:ERG was performed to study the impact of ERG silencing on cell proliferation and cell cycle distribution in prostate cancer cells. The results demonstrated that the TMPRSS2 and ERG genes were mostly altered in prostate cancer, and the most frequent alteration was gene fusion. Oncomine analysis demonstrated that the ERG gene was significantly upregulated in prostate clinical samples compared with the normal prostate gland in four independent datasets, and a positive association was observed between potassium inwardly‑rectifying channel subfamily J member 15, down syndrome critical region gene 4, potassium inwardly‑rectifying channel subfamily J member 6 and ERG gene expression. There were 272 mutations of the ERG gene identified in the cBioPortal database; among the mutations, 2 missense mutations (R367C and P401H) were regarded as functional mutations (functional impact score >1.938). Furthermore, the present study successfully knocked down ERG gene expression through a lentiviral‑mediated gene silencing approach in VCaP prostate cancer cells. The ERG mRNA and protein expression levels were both suppressed significantly, and a cell‑cycle arrest at G0/G1 phase was observed after ERG gene silencing. In conclusion, these bioinformatics analyses provide novel insights for TMPRSS2:ERG fusion gene study in prostate cancer. Target inhibition of ERG expression could significantly cause cell growth arrest in prostate cancer cells, which could be a potentially valuable target for prostate cancer treatment. However, the precise mechanism of these results remains unclear; therefore, further studies are required.

Indexed as

Biomarkers, TumorCell CycleCell Line, TumorCell ProliferationComputational BiologyDatabases, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticGene FrequencyGene Regulatory NetworksGenetic VariationHumansMaleMutationOncogene Proteins, FusionPrognosisBiomarkers, TumorOncogene Proteins, FusionRNA, Small InterferingSerine EndopeptidasesTMPRSS2-ERG fusion protein, humanTMPRSS2 protein, humanTranscriptional Regulator ERG

Identifiers

PMID28849022
PMCPMC5647090
OpenAlexW2747733421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.